$ARMP
Armata Pharmaceuticals, Inc.

2018 Q4 Form 10-K Financial Statement

#000114420419015711 Filed on March 25, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $0.00 $0.00 $20.00K
YoY Change -100.0% -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.475M $5.702M $1.300M
YoY Change 13.46% -24.87% -15.58%
% of Gross Profit
Research & Development $1.375M $4.892M $1.090M
YoY Change 26.15% 69.8% 36.25%
% of Gross Profit
Depreciation & Amortization $90.00K $358.0K $90.00K
YoY Change 0.0% 4.37% -10.0%
% of Gross Profit
Operating Expenses $2.850M $12.52M $2.390M
YoY Change 19.25% -23.03% 2.14%
Operating Profit -$12.52M
YoY Change -22.48%
Interest Expense $132.0K $86.00K $10.00K
YoY Change 1220.0% -95.72% -99.53%
% of Operating Profit
Other Income/Expense, Net $0.00 $86.00K $0.00
YoY Change -95.73% -100.0%
Pretax Income -$4.648M -$7.221M -$2.350M
YoY Change 97.79% 4.14% -76.64%
Income Tax -$328.0K -$328.0K $0.00
% Of Pretax Income
Net Earnings -$4.320M -$12.11M -$2.350M
YoY Change 83.83% -5.67% -75.26%
Net Earnings / Revenue -11750.0%
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$2.038M -$0.64 -$3.456M
COMMON SHARES
Basic Shares Outstanding 32.29M 18.98M
Diluted Shares Outstanding 19.06M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.157M $8.157M $5.130M
YoY Change 59.01% 58.94% -10.16%
Cash & Equivalents $8.157M $8.157M $5.132M
Short-Term Investments
Other Short-Term Assets $251.0K $251.0K $250.0K
YoY Change 0.4% -0.79% -58.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.408M $8.408M $5.385M
YoY Change 56.14% 56.14% -14.66%
LONG-TERM ASSETS
Property, Plant & Equipment $503.0K $503.0K $816.0K
YoY Change -38.36% -38.36% -23.74%
Goodwill
YoY Change
Intangibles $2.731M $4.661M
YoY Change -41.41%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $3.479M $3.479M $5.753M
YoY Change -39.53% -39.53% -51.41%
TOTAL ASSETS
Total Short-Term Assets $8.408M $8.408M $5.385M
Total Long-Term Assets $3.479M $3.479M $5.753M
Total Assets $11.89M $11.89M $11.14M
YoY Change 6.72% 6.72% -38.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $729.0K $729.0K $578.0K
YoY Change 26.12% 26.12% -78.91%
Accrued Expenses $1.805M $1.805M $1.390M
YoY Change 29.86% 33.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.572M $2.572M $1.968M
YoY Change 30.69% 30.69% -44.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.00K $22.00K $290.0K
YoY Change -92.41% -92.47% -88.11%
Total Long-Term Liabilities $22.00K $22.00K $290.0K
YoY Change -92.41% -92.47% -88.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.572M $2.572M $1.968M
Total Long-Term Liabilities $22.00K $22.00K $290.0K
Total Liabilities $3.413M $3.413M $3.407M
YoY Change 0.18% 0.18% -59.58%
SHAREHOLDERS EQUITY
Retained Earnings -$406.3M -$394.2M
YoY Change 3.07%
Common Stock $323.0K $95.00K
YoY Change 240.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.474M $8.474M $7.731M
YoY Change
Total Liabilities & Shareholders Equity $11.89M $11.89M $11.14M
YoY Change 6.72% 6.72% -38.63%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$4.320M -$12.11M -$2.350M
YoY Change 83.83% -5.67% -75.26%
Depreciation, Depletion And Amortization $90.00K $358.0K $90.00K
YoY Change 0.0% 4.37% -10.0%
Cash From Operating Activities -$2.428M -$9.382M -$2.370M
YoY Change 2.45% 2.07% 58.0%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $44.00K -$20.00K
YoY Change -85.0% -24.14% 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$3.000K -$44.00K -$20.00K
YoY Change -85.0% -24.14% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.089M 12.45M -210.0K
YoY Change -2999.52% 43.59% -106.44%
NET CHANGE
Cash From Operating Activities -2.428M -9.382M -2.370M
Cash From Investing Activities -3.000K -44.00K -20.00K
Cash From Financing Activities 6.089M 12.45M -210.0K
Net Change In Cash 3.658M 3.025M -2.600M
YoY Change -240.69% -622.45% -248.57%
FREE CASH FLOW
Cash From Operating Activities -$2.428M -$9.382M -$2.370M
Capital Expenditures -$3.000K $44.00K -$20.00K
Free Cash Flow -$2.425M -$9.426M -$2.350M
YoY Change 3.19% 1.9% 57.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 aphb Common Stock Issued In Financing Offering Three Net Of Offering Costs
CommonStockIssuedInFinancingOfferingThreeNetOfOfferingCosts
9353000
CY2018 aphb Common Stock Issued In Financing Offering Three Net Of Offering Costs
CommonStockIssuedInFinancingOfferingThreeNetOfOfferingCosts
5830000
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
453000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
578000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
401842000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
414467000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
729000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1170000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1528000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
700000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
478000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
478000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
31000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
31000
CY2017 aphb Dilutive Financing Derivative Liability Reclassified To Equity Upon Common Stock Issued Pursuant To Anti Dilution Rights Value
DilutiveFinancingDerivativeLiabilityReclassifiedToEquityUponCommonStockIssuedPursuantToAntiDilutionRightsValue
22000
CY2017 aphb Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
-0.056
CY2018 aphb Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
-0.001
CY2017 aphb Liabilities Fair Value Adjustment Including Exercise Price Adjustment
LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment
-1524000
CY2018 aphb Liabilities Fair Value Adjustment Including Exercise Price Adjustment
LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment
-55000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
302000
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
5800000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1930000
CY2017Q4 us-gaap Assets
Assets
11138000
CY2018Q4 us-gaap Assets
Assets
11887000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
5385000
CY2017 aphb Warrants Exercised During Period
WarrantsExercisedDuringPeriod
226664
CY2018 aphb Warrants Exercised During Period
WarrantsExercisedDuringPeriod
217400
CY2017 aphb Warrants Expired During Period
WarrantsExpiredDuringPeriod
17683
CY2018 aphb Warrants Expired During Period
WarrantsExpiredDuringPeriod
28331
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32294008
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
4000000
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
3000000
CY2017 aphb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
130000
CY2018 aphb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
198000
CY2017 aphb Taxcutsandjobsactof2017incometaxexpensebenefit
Taxcutsandjobsactof2017incometaxexpensebenefit
26000000
CY2017 aphb Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit Incomplete Accounting Provisional Amount
TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefitIncompleteAccountingProvisionalAmount
0
CY2018 aphb Unpaid Offering Costs
UnpaidOfferingCosts
260000
CY2017 aphb Warrant Derivative Liability Reclassified To Equity Due To Exercise Of Warrants
WarrantDerivativeLiabilityReclassifiedToEquityDueToExerciseOfWarrants
119000
CY2018 aphb Warrant Derivative Liability Reclassified To Equity Due To Exercise Of Warrants
WarrantDerivativeLiabilityReclassifiedToEquityDueToExerciseOfWarrants
184000
CY2018Q2 dei Entity Public Float
EntityPublicFloat
18600000
CY2018 dei Entity Registrant Name
EntityRegistrantName
AmpliPhi Biosciences Corp
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Trading Symbol
TradingSymbol
APHB
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1968000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2572000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28111252
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9340952
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8408000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5711000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5132000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8157000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-579000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3025000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26961187
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
28603950
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
670000000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9948928
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32294008
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9498928
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32294008
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
95000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
323000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1302000
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-328000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1302000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-328000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47511000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47148000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44049000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44157000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
165000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
196000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3109000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2523000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
188000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
272000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47511000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47148000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1147000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
819000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1147000
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
819000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1147000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
819000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
12000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2000
CY2017 us-gaap Depreciation
Depreciation
343000
CY2018 us-gaap Depreciation
Depreciation
358000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2010000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
86000
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
292000
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
22000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
292000
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22000
CY2017Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
38000
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
38000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
31000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
31000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
276000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
245000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-838000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
343000
CY2017 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2010000
CY2018 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-86000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-381000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.092
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.028
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.709
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.034
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.842
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.044
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.036
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.024
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.046
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.003
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.203
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.032
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.017
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.003
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1050000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1352000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
630000
CY2018Q4 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
46472
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
184000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
90000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
31000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
31000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
31000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7590000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5702000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-12110000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14362000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6934000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7221000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-7206000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5217000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14140000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12438000
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1302000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-328000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4661000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2731000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
519000
CY2017Q4 us-gaap Liabilities
Liabilities
3407000
CY2018Q4 us-gaap Liabilities
Liabilities
3413000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11138000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11887000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1968000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2572000
CY2018 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-86000
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
115000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8671000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12451000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9192000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9382000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12838000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12165000
CY2017 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
39000
CY2017 us-gaap Operating Expenses
OperatingExpenses
16271000
CY2018 us-gaap Operating Expenses
OperatingExpenses
12524000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-16156000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-12524000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
293000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
81000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
11000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
67000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
67000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
67000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
208000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
210000
CY2017 us-gaap Other Noncash Expense
OtherNoncashExpense
22000
CY2017 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2016000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2881000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4892000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
253000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
251000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5000
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9353000
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12248000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3400000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2800000
CY2017 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-815000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
130000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
198000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1986000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2031000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
816000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394206000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406316000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.86
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M23D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29597
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3300
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1070572
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
37500
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
74890
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1115865
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M23D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
864952
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4000000
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2743640
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.10
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1150065
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.50
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.17
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
700000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
478000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
446226
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
402642
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.79
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M11D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
87.87
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.54
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.22
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.18
CY2018Q4 us-gaap Share Price
SharePrice
0.21
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
9723000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
7731000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8474000
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2018 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 (1:10) reverse stock split of its common stock, par value $0.01 per share
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6158000
CY2017 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
519000
CY2018 us-gaap Substantial Doubt About Going Concern Managements Evaluation
SubstantialDoubtAboutGoingConcernManagementsEvaluation
Considering the Company's current cash resources, management believes the Company's existing resources, without considering any effect of the pending merger with C3J and related financing, will be sufficient to fund the Company's planned operations into mid-2019.
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font> </p> <p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6574117
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19059895
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6387425
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18980796

Files In Submission

Name View Source Status
0001144204-19-015711-index-headers.html Edgar Link pending
0001144204-19-015711-index.html Edgar Link pending
0001144204-19-015711.txt Edgar Link pending
0001144204-19-015711-xbrl.zip Edgar Link pending
aphb-20181231.xml Edgar Link completed
aphb-20181231.xsd Edgar Link pending
aphb-20181231_cal.xml Edgar Link unprocessable
aphb-20181231_def.xml Edgar Link unprocessable
aphb-20181231_lab.xml Edgar Link unprocessable
aphb-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv514748_10k.htm Edgar Link pending
tv514748_ex10-18.htm Edgar Link pending
tv514748_ex10-18img1.jpg Edgar Link pending
tv514748_ex2-5.htm Edgar Link pending
tv514748_ex21-1.htm Edgar Link pending
tv514748_ex23-1.htm Edgar Link pending
tv514748_ex31-1.htm Edgar Link pending
tv514748_ex31-2.htm Edgar Link pending
tv514748_ex32-1.htm Edgar Link pending
tv514748_ex32-2.htm Edgar Link pending
tv514748_img1.jpg Edgar Link pending
tv514748_img2.jpg Edgar Link pending
tv514748_img3.jpg Edgar Link pending
tv514748_img4.jpg Edgar Link pending
tv514748_img5.jpg Edgar Link pending
tv514748_img6.jpg Edgar Link pending